285 related articles for article (PubMed ID: 29626514)
1. Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution.
van der Heiden P; Marijt E; Falkenburg F; Jedema I
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1776-1782. PubMed ID: 29626514
[TBL] [Abstract][Full Text] [Related]
2. Possible Impact of Cytomegalovirus-Specific CD8
Ogonek J; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Borchers S; Koehl U; Weissinger EM; Hambach L
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1046-1053. PubMed ID: 28344058
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
6. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.
Hakki M; Riddell SR; Storek J; Carter RA; Stevens-Ayers T; Sudour P; White K; Corey L; Boeckh M
Blood; 2003 Oct; 102(8):3060-7. PubMed ID: 12843000
[TBL] [Abstract][Full Text] [Related]
7. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
[TBL] [Abstract][Full Text] [Related]
8. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
Gondo H; Himeji D; Kamezaki K; Numata A; Tanimoto T; Takase K; Aoki K; Henzan H; Nagafuji K; Miyamoto T; Ishikawa F; Shimoda K; Inaba S; Tsukamoto H; Horiuchi T; Nakashima H; Otsuka T; Kato K; Kuroiwa M; Higuchi M; Shibuya T; Kamimura T; Kuzushima K; Tsurumi T; Kanda Y; Harada M
Int J Hematol; 2004 Dec; 80(5):441-8. PubMed ID: 15646657
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
[TBL] [Abstract][Full Text] [Related]
12. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
13. Rapid reconstitution of CMV-specific T-cells after stem-cell transplantation.
Widmann T; Sester U; Schmidt T; Gärtner BC; Schubert J; Pfreundschuh M; Sester M
Eur J Haematol; 2018 Jul; 101(1):38-47. PubMed ID: 29652096
[TBL] [Abstract][Full Text] [Related]
14. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
15. Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.
La Rosa C; Longmate J; Lingaraju CR; Zhou Q; Kaltcheva T; Hardwick N; Aldoss I; Nakamura R; Diamond DJ
Biol Blood Marrow Transplant; 2019 Apr; 25(4):771-784. PubMed ID: 30562587
[TBL] [Abstract][Full Text] [Related]
16. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R
PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation.
Foster AE; Gottlieb DJ; Sartor M; Hertzberg MS; Bradstock KF
Biol Blood Marrow Transplant; 2002; 8(9):501-11. PubMed ID: 12374455
[TBL] [Abstract][Full Text] [Related]
18. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
[TBL] [Abstract][Full Text] [Related]
19. CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.
van der Heiden PLJ; van Egmond HM; Veld SAJ; van de Meent M; Eefting M; de Wreede LC; Halkes CJM; Falkenburg JHF; Marijt WAF; Jedema I
Transpl Immunol; 2018 Aug; 49():54-58. PubMed ID: 29679650
[TBL] [Abstract][Full Text] [Related]
20. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.
Widmann T; Sester U; Gärtner BC; Schubert J; Pfreundschuh M; Köhler H; Sester M
PLoS One; 2008; 3(11):e3634. PubMed ID: 18982061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
